IRHYTHM HOLDINGS INC
IRTCNASDAQTrading Snapshot
- Day Range
- $120.44 – $123.78
- 52-Week Range
- $100.85 – $212.00
- Volume
- $3.67B
- Avg Volume
- $4.32B
- Shares Outstanding
- 32.9M
- Next Earnings
- Oct 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $747M
- Last Q Revenue
- $224M
- P/E Ratio
- —
- P/S Ratio
- 5.1x
- EPS (TTM)
- $-0.86
- Dividend Yield
- —
Why Investors Own IRTC
- ✓High-growth profile — revenue up +56.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 52% gross margin and 27% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About IRHYTHM HOLDINGS INC
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Truist Securities Maintains Buy on iRhythm Holdings, Raises Price Target to $168
Truist Securities analyst Richard Newitter maintains iRhythm Holdings (NASDAQ:IRTC) with a Buy and raises the price target from $160 to $168.
iRhythm Holdings, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-07. The following slide deck was published by iRhythm Holdings, Inc.
iRhythm Combines Strong Performance with VitalConnect Buy to Expand Remote Cardiac Care
iRhythm to acquire VitalConnect for $287.5 million, expands cardiac monitoring portfolio after Q2 earnings beat and higher fiscal 2026 guidance.
Wells Fargo Maintains Overweight on iRhythm Holdings, Lowers Price Target to $168
Wells Fargo analyst Nathan Treybeck maintains iRhythm Holdings (NASDAQ:IRTC) with a Overweight and lowers the price target from $180 to $168.
Needham Maintains Buy on iRhythm Holdings, Lowers Price Target to $192
Needham analyst David Saxon maintains iRhythm Holdings (NASDAQ:IRTC) with a Buy and lowers the price target from $255 to $192.
Evercore ISI Group Maintains Outperform on iRhythm Holdings, Raises Price Target to $165
Evercore ISI Group analyst Vijay Kumar maintains iRhythm Holdings (NASDAQ:IRTC) with a Outperform and raises the price target from $150 to $165.